Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 23;42(3):234-241.
doi: 10.3760/cma.j.cn112152-20190705-00413.

[Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma]

[Article in Chinese]
Affiliations

[Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma]

[Article in Chinese]
P Liu et al. Zhonghua Zhong Liu Za Zhi. .

Abstract

Objective: To investigate the clinical features, survival and prognostic factors of elder patients with diffuse large B-cell lymphoma (DLBCL). Methods: The clinical data of elder patients with diffuse large B-cell lymphoma enrolled in the Cancer Hospital of Chinese Academy of Medical Sciences from April 2006 to December 2012 were retrospectively collected. All the patients were divided into R-CHOP-like group and CHOP-like group according to the dosage regimen. And the differences in demographic characteristics, clinical features, survival time and prognostic factors were compared between these two groups. Results: A total of 158 patients were enrolled, of which 78 patients in the R-CHOP-like group and 80 patients in the CHOP-like group were eligible. There were no significant differences between two groups on age, gender, pathological staging, B symptoms, bulky mass, ECOG score, IPI score, pathological type, LDH level, β(2)-MG level, lymphocyte/monocyte ratio(LMR), neutrophils/lymphocyte ratio(NLR), platelet/lymphocyte ratio(PLR), Ki-67 index and bone marrow invasion. In the R-CHOP like group, the median progression-free survival (PFS) time was 10 months, and the median overall survival (OS) time was 30 months. The 1-year and 2-year PFS rates were 46.2% and 19.2%, respectively. The 1-, 2-, and 5-year OS rates were 79.5%, 59.0%, and 19.2%, respectively. In the CHOP-like group, the median PFS was 7 months, and the median OS was 15 months. The 1-year and 2-year PFS rates were 27.5% and 12.5% respectively. The 1-year, 2-year, and 5-year OS rates were 65.0%, 32.5% and 13.8%, respectively. The median PFS time and OS time in the R-CHOP group were significantly better than those in the CHOP group (P<0.05 for both). A stratified analysis showed that the PFS time and OS time were superior in the R-CHOP-like group compared to the CHOP-like group among patients older than 70 years (P<0.05 for both). In patients with stage Ⅲ-Ⅳ, the PFS time and OS time in the R-CHOP-like group were also superior to CHOP-like group (P<0.05 for both). Univariate Cox regression analysis showed that IPI score, LDH value, β(2)-MG value, ECOG score, LMR, and PLR had an significant effect on prognosis (P<0.05 for all). Multivariate Cox regression analysis showed that lymphocyte/monocyte ratio and platelet/lymphocyte ratio were independent prognostic factors for diffuse large B-cell lymphoma (P<0.05 for both). Conclusions: The R-CHOP-like chemotherapy regimen is superior to the CHOP-like regimen in the first-line treatment of patients with diffuse large B-cell lymphoma. ECOG score, LMR and PLR may be independent prognostic factors for diffuse large B-cell lymphoma. ECOG score, LMR and PLR are independent prognostic factors.

目的: 探讨老年弥漫大B细胞淋巴瘤(DLBCL)患者的临床特征、生存情况和预后影响因素。 方法: 回顾性分析中国医学科学院肿瘤医院2006年4月至2012年12月间收治的老年DLBCL患者的临床资料,按给药方案分为R-CHOP样组或CHOP样组,分析比较不同治疗方案组患者的临床特征、生存情况及预后影响因素。 结果: 共纳入158例患者,R-CHOP样组78例,CHOP样组80例。R-CHOP样组和CHOP样组患者的年龄、性别、疾病分期、B症状、大肿块、美国东部肿瘤协作组(ECOG)评分、国际预后指数(IPI)评分、病理类型、乳酸脱氢酶(LDH)水平、β(2)微球蛋白(β(2)-MG)水平、淋巴细胞单核细胞比(LMR)、嗜中性粒细胞淋巴细胞比(NLR)、血小板淋巴细胞比(PLR)、Ki-67指数、骨髓受侵等临床特征的差异均无统计学意义(均P>0.05)。R-CHOP样组患者的中位无进展生存时间(PFS)为10个月,中位总生存时间(OS)为30个月,1年、2年无进展生存率分别为46.2%和19.2%,1年、2年、5年总生存率分别为79.5%、59.0%和19.2%。CHOP样组患者的中位PFS为7个月,中位OS为15个月,1年、2年无进展生存率分别为27.5%和12.5%,1年、2年、5年总生存率分别为65.0%、32.5%和13.8%。R-CHOP样组患者的中位PFS和中位OS均明显优于CHOP样组(均P<0.05)。在>70岁患者中,R-CHOP样组患者的中位PFS和中位OS均优于CHOP样组(均P<0.05);在Ⅲ~Ⅳ期患者中,R-CHOP样组患者的中位PFS和中位OS均优于CHOP样组(均P<0.05)。单因素Cox回归分析显示,IPI评分、LDH水平、β(2)-MG水平、ECOG评分、LMR和PLR与DLBCL患者的预后有关(P<0.05)。多因素Cox回归分析显示,ECOG评分、LMR和PLR是老年DLBCL的独立预后影响因素(P<0.05)。 结论: R-CHOP样化疗方案一线治疗老年DLBCL患者的疗效优于CHOP样方案,ECOG评分、LMR和PLR为老年DLBCL患者的独立预后影响因素。.

Keywords: Clinical features; Curative effect; Elderly people; Non-Hodgkin′s lymphoma; Prognostic factors.

PubMed Disclaimer

Similar articles